Skip to main content
. 2022 Nov 6;42(12):1314–1330. doi: 10.1002/cac2.12385

FIGURE 2.

FIGURE 2

Kaplan‐Meier survival curve of overall survival in the full analysis set. The median OS was 11.79 (95% CI, 10.28‐15.57) months in the sintilimab arm and 8.25 (95% CI, 6.47‐9.82) months in the docetaxel arm. Sintilimab significantly improved OS compared with docetaxel with a HR of 0.74 (95% CI, 0.56‐0.96; P = 0.025).

Abbreviations: OS, overall survival; CI, confidence interval; HR, hazard ratio